Cipher Pharmaceuticals Inc.

Toronto Stock Exchange:CPH.TO

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💄 Cosmetics

💊 Drugstores & Retail Pharmacies

Location

Canada

Market Cap

USD 240.79 M

Share Price

USD 9.40

Avg Daily Volume

29,123

Change (1 day)

0.12%

Change (1 year)

51.78%

Change (YTD)

-5.56%

Cipher Pharmaceuticals Inc. Free Cash Flow for the year ending December 31, 2024: USD 19.50 M

Cipher Pharmaceuticals Inc. Free Cash Flow is USD 19.50 M for the year ending December 31, 2024, a 22.06% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Cipher Pharmaceuticals Inc. Free Cash Flow for the year ending December 31, 2023 was USD 15.98 M, a 52.26% change year over year.
Cipher Pharmaceuticals Inc. Free Cash Flow for the year ending December 31, 2022 was USD 10.49 M, a -24.03% change year over year.
Cipher Pharmaceuticals Inc. Free Cash Flow for the year ending December 31, 2021 was USD 13.81 M, a 26.37% change year over year.
Cipher Pharmaceuticals Inc. Free Cash Flow for the year ending December 31, 2020 was USD 10.93 M, a 44.80% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

Toronto Stock Exchange: CPH.TO

Cipher Pharmaceuticals Inc.

CEO	Mr. Craig J. Mull
IPO Date	May 7, 2004
Location	Canada
Headquarters	209 Oak Park Boulevard
Employees	5
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💄 Cosmetics 💊 Drugstores & Retail Pharmacies

Description

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.